Business / Finance

RSS

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Ben-Gurion University of the Negev and the PTT Chemical Public Company Ltd. in Thailand have signed a research and development collaboration agreement for commercial development of BGU's proprietary green algae strain.

29 Jan 2011

Awarepoint ends 2010 with 91 hospital sites contract containing RTLS network coverage

Awarepoint Corporation, a privately held San Diego-based corporation, today announced it ended 2010 with 91 hospital sites contracted consisting of 45,062,013 million square feet of real-time location system network coverage in U.S. hospitals and 135,265 healthcare assets under management.

29 Jan 2011

BioTime announces acquisition of CTI assets

BioTime, today announced that it has acquired substantially all the assets of Cell Targeting, a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine.

29 Jan 2011

Synutra International renews manufacturing license for its primary production facility

Synutra International, Inc., a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today announced that it has renewed its manufacturing license for its primary production facility with the Shandong Bureau of Quality and Technical Supervision.

29 Jan 2011

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

XDx, a San Francisco-based molecular diagnostics company focused on non-invasive gene expression-based tests for the monitoring of organ transplant rejection and autoimmune diseases, announced today that it has established a $12.5 million senior secured multi-draw term loan facility with GE Capital, Healthcare Financial Services.

28 Jan 2011

IDEXX Laboratories fourth quarter revenues increase 5% to $283.8 million

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2010 increased 5% to $283.8 million, from $270.3 million for the fourth quarter of 2009. Organic revenue growth, as defined below, was 6%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2010 increased 22% to $0.62, compared to $0.51 for the same period in the prior year.

28 Jan 2011

H.I.G. urges Matrixx shareholders to evaluate BML Letter regarding pending tender offer

H.I.G. Capital, LLC, a leading global private investment firm, today announced that it has reviewed the letter addressed to the Board of Directors of Matrixx Initiatives, Inc. from BML Capital Management, LLC, dated January 25, 2011, regarding the pending tender offer for all of the outstanding shares of common stock of Matrixx by Wonder Holdings, Inc. and Wonder Holdings Acquisition Corp., both affiliates of H.I.G. formed for the purpose of acquiring Matrixx.

28 Jan 2011

Taro fourth quarter net sales increase 22.7% to $102.2 million

Taro Pharmaceutical Industries Ltd. today provided preliminary, unaudited and unreviewed financial results for the quarter and year ended December 31, 2010.

28 Jan 2011

EHSI examines business plans and product lines of OceanBASIS

Emerging Healthcare Solutions, Inc. is examining the business plans and product lines of German biotech firm OceanBASIS as part of the company's due diligence towards a potential profit sharing agreement.

28 Jan 2011

Quality Systems third quarter net revenues increase 23% to record $91.9 million

Quality Systems, Inc. announced today the results of operations for its fiscal 2011 third quarter ended December 31, 2010.

28 Jan 2011

Bioniche Life Sciences joins Australian Securities Exchange

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has joined the official list of the Australian Securities Exchange (ASX) and its securities are now trading on that exchange under the code "BNC".

28 Jan 2011

Arena reduces workforce by 25% and provides update on lorcaserin

Arena Pharmaceuticals, Inc. announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of 2011, of approximately $3.8 million in connection with one-time employee termination costs.

28 Jan 2011

Inovio to use proceeds from $24.3M offering for development of DNA vaccine against cervical dysplasias

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock.

28 Jan 2011

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec Pharmaceuticals today announced that it has granted multiple non-exclusive licenses to generic manufacturers including Hetero Drugs Limited, Matrix Laboratories Limited (a Mylan company) of India and Aspen Pharmacare of South Africa to manufacture, market and distribute the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278), pending its approval for use with other antiretroviral agents in the treatment of treatment-naive HIV-1 infected adults.

28 Jan 2011

Pfizer announces termination of HSR waiting period for acquisition of King

Pfizer Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has been terminated in connection with the tender offer by its wholly-owned subsidiary, Parker Tennessee Corp., to purchase all outstanding shares of common stock of King Pharmaceuticals, Inc. for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

27 Jan 2011

Zimmer fourth quarter net sales increase 2.5% to $1.13 billion

Zimmer Holdings, Inc. today reported financial results for the quarter and year ended December 31, 2010. The Company reported fourth quarter net sales of $1.13 billion, an increase of 2.5% reported and 3.0% constant currency over the fourth quarter of 2009.

27 Jan 2011

Fresenius Medical Care prices US$ senior notes

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced the pricing of US$-denominated and €-denominated senior unsecured notes in the principal amounts of US$650 million and €300 million, respectively, both due 2021.

27 Jan 2011

Mead Johnson's 2010 GAAP net earnings increase to $2.20 per diluted share

"We concluded the year on a strong note reporting record sales and earnings for 2010," said Chief Executive Officer Stephen W. Golsby. "The year unfolded as expected with Asia and Latin America continuing to deliver double-digit sales growth and the North America/Europe segment growing in the low single-digits.

27 Jan 2011

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

Despite reimbursement cuts the diagnostic imaging market to grow at 5% over next five years: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, although the overall diagnostic imaging market has been limited by reimbursement cuts and poor economic conditions, the next five years will see unit growth of approximately 5%.

27 Jan 2011